Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$27.4 million.

  • Myriad Genetics' Net Income towards Common Stockholders fell 2398.19% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.5 million, marking a year-over-year decrease of 24525.86%. This contributed to the annual value of -$127.3 million for FY2024, which is 5165.21% up from last year.
  • Latest data reveals that Myriad Genetics reported Net Income towards Common Stockholders of -$27.4 million as of Q3 2025, which was down 2398.19% from -$330.5 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Net Income towards Common Stockholders peaked at $24.6 million during Q3 2021, and registered a low of -$330.5 million during Q2 2025.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$31.2 million (2023), whereas its average is -$46.7 million.
  • As far as peak fluctuations go, Myriad Genetics' Net Income towards Common Stockholders surged by 26184.21% in 2021, and later crashed by 80054.5% in 2025.
  • Myriad Genetics' Net Income towards Common Stockholders (Quarter) stood at -$7.6 million in 2021, then tumbled by 456.58% to -$42.3 million in 2022, then increased by 26.24% to -$31.2 million in 2023, then plummeted by 36.22% to -$42.5 million in 2024, then surged by 35.53% to -$27.4 million in 2025.
  • Its Net Income towards Common Stockholders was -$27.4 million in Q3 2025, compared to -$330.5 million in Q2 2025 and -$100000.0 in Q1 2025.